|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
• SWI-LIV is significantly increased in high-grade and IDH1-R132H negative gliomas.
|
27300198 |
2017 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We report that glioma cells showing the IDH1(R132H) mutation become rapidly and spontaneously senescent in vitro.
|
24922649 |
2014 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We identified a single significant correlation resulting in increased overall survival from temozolomide in lower-grade glioma with IDH1 R132H mutations.
|
26936071 |
2016 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We earlier established a monoclonal antibody (mAb), IMab-1, which is specific for R132H-containing IDH1 (IDH1-R132H), the most frequent IDH1 mutation in gliomas.
|
21352804 |
2011 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We developed and validated a new real-time quantitative polymerase chain reaction (PCR) assay for single-step detection of IDH1 R132H and 11 rare IDH1/2 mutations in formalin-fixed paraffin-embedded (FFPE) glioma samples.
|
24889502 |
2014 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Using murine glioma progenitor cells, we demonstrate that IDH1(R132H) exerts a growth-inhibitory effect that is paralleled by deficiency in metabolic flux from glucose and glutamine to lipids.
|
25225364 |
2014 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study is to understand the effects of IDH1 R132H mutation in gliomagenesis and to develop new strategies to treat glioma with IDH1 R132H mutation.
|
28052098 |
2017 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study analyses a series of 184 glioma cases in a tissue microarray (TMA)-based approach to assess the frequency of R132H point mutations in formalin-fixed, paraffin-embedded tissue samples.
|
23361281 |
2013 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This novel series of IDH1(R132H) inhibitors have potential to be further developed for the treatment of glioma with IDH1 mutation.
|
29792149 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This case suggests that 1p/19q co-deletion may rarely precede IDH1 mutations or that IDH1 mutations may be secondarily lost, as demonstrated by IDH1-R132H positive and negative cells in a glioma with diffuse 1p/19q co-deletion.
|
25907263 |
2016 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This glioma xenograft is the first to display a pure oligodendroglioma histology and expression of R132H.
|
23527265 |
2013 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These results support a role for Fn14 in the more aggressive and invasive phenotype associated with IDH1 WT tumors and indicate that the low levels of Fn14 gene expression noted in IDH1 R132H mutant gliomas may be due to epigenetic regulation via changes in DNA methylation.
|
29453678 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The isocitrate dehydrogenase 1 (IDH1) R132H mutation is the most common mutation in World Health Organization (WHO) grade II gliomas, reported to be expressed in 70-80%, but only 5-10% of high grade gliomas.
|
24903073 |
2014 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors.
|
27655638 |
2016 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The R132H mutation in isocitrate dehydrogenase 1 (IDH1-R132H) is associated with better prognosis in glioma patients.
|
29115585 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Small-size DNA (150-250 base pairs) was extracted from the plasma of 31 controls and 80 patients with glioma with known IDH1(R132H) status and correlated with MRI data.
|
23035067 |
2012 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Sequencing for rare IDH mutations is advised for A,NOS and OA,NOS groups, but not for the IDH1(R132H)-non-mutant diffuse gliomas with 1p/19q co-deletion.
|
28801347 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Recurrent heterozygous mutation of isocitrate dehydrogenase 1 gene (<i>IDH1</i>), predominantly resulting in histidine substitution at arginine 132, was first identified in glioma.
|
30416682 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients/Methods In a prospective cohort study, intratumoral IDH1 R132H mutation and podoplanin were determined in brain tumor specimens (mainly glioma) by immunohistochemistry.
|
29676036 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Overall, our results provide evidence that the IDH1-R132H mutation alters phospholipid metabolism in gliomas involving phosphoethanolamine and glycerophosphocholine.
|
25005896 |
2014 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results suggest that the pathogenesis of multicentric gliomas is different from the mutant IDH1-R132H pathogenesis of lower-grade glioma and secondary glioblastomas.
|
27553586 |
2017 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results indicate the usefulness of assessing the R132H IDH1 mutation in glioma patients: the presence or absence of the R132H mutation can help pathologists to distinguish pilocytic astrocytomas (IDH1 WT) from diffuse ones (R132H IDH1/WT).
|
23934769 |
2014 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
|
29625108 |
2018 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort.
|
23934175 |
2013 |
|
rs121913500
|
|
Glioma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutations of isocitrate dehydrogenase-1 gene (IDH1), most commonly resulting in replacement of arginine at position 132 by histidine (R132H), have been described in World Health Organization grade II and III diffuse gliomas and secondary glioblastoma.
|
22445362 |
2012 |